Form	PT	0.14	40			116	- D			ent of Comm		1		T	ge i oi i
		U-14	~/			Pa	teni	an	d Tr	ademark O	ffice	Atty. Doc. 60390-1A/	ket No. IPW/GJG/JBC	Serial Not Ye	No. et Know
				JEO			1101				1700		s: Arlindo Cas		
			TI.	4F C						LOSURE C		Filing Date Herewith		Group	
										U.S. PA	ATENT DOCUMENTS	literewith			
Examlı Initial	ner 0		Do	cum	ent P	iuml	er			Date Name		Class	Subclass	Filing E)ate
A	1	3 0 3 7 9 8					9	8	0	6/5/62	Hitchings, G.H. et al.;		 	if Appr	opriate
<i>₹1.</i>		+-	3	6	1	6	6	╁	- 13	10/7/75	Kim, et al.;		//	 	
-f		╁	5	2	0	8	2	4	0	5/4/93		+		 	
\dashv		+-	5	4	0	9	9	3	6	4/25/95	Peet, et al.;	++	 /	 	
一十		+	5	5	Ť	6	8	6	4	5/14/96	Spada, A.P. et al.;		 	<u> </u>	
-		┼─	5	5	8	6	8	卡	6	12/3/96	Reppen, S.M.;	 	 		
-+		 	5	6	3	6	6	╁	3		Barker, A.J. et al.;	 	 		
\dashv		╁╌	5	6	4	6			6	6/17/97	Lidor et al.;	 			
		 - -	5	6	8		#	5	- -	7/8/97	Jacobson et al.;		\ /		
\dashv		┿┈	5	7	 	0	9	4	1	10/28/97	Cook, P.D. et al.;		IV		
		┼—		<u> </u>	╬		 -	5	8	1/20/98	Myers, M.R. et al.;		ΙΔ		
-			5	7	<u></u>	4	4	9	3	2/3/98	Myers, M.R. et al.;		<u> </u>		
		├	5	2	2	╙	2	3	7	2/24/98	Myers, M.R. et al.;		<u> </u>		
		<u> </u>	5	7	4	7	4	9	8	5/5/98	Schnur, R.C. et al.;		1		
_			5	7	8	0	4	5	0	7/14/98	Shade, D.L. et al.;			1 —	
			5	7	8	0	4	8	1	7/14/98	Jacobson et al.;	1		╅	
			5	8	3	4	6	0	9	11/10/98	Horne, D.A. et al.;	 	- \ 	+	
			5	8	7	7	2	ī	8	3/2/99	Herzig et al.;	 		 	
			5	8	7	7	2	2	1	3/2/99	Cohen et al.;	 			
			5	8	8	0	1	5	9	3/9/99	Herzig et al.;	 		 	
			5	9	1	4	3	4	9	6/22/99	Cohen et al.:	 		+ -	
			5	9	6	2	4	5	8	10/5/99	Lohmann et al.;	 			
	_		5	9	9	4	4	0	8	11/30/99	Cohen et al.;	 		 	
An	N		6	ī	0	3	8	9	9	8/15/00	Horne, D.A. et al.	+/		 	
					<u>1</u>	1~	1	1	12.		PATENT DOCUMENTS	5		Т	
			Do	cum	ent	Nu	mbe	er:		Date	Country	Class	Subclass	Translation	
		<u> </u>												Yes	No
\dot{W}	<u>L</u> ,			3	2	0	0	7	8	10/14/93	PCT;				
W\	<u></u>	wo	9	4	1	3	6	7	6	6/23/94	PCT;				
<u> </u>	4	wo	9	4	1	7	0	9	0	8/4/94	PCT;				-
				0	TH	ER	DO	CU	ME	NTS (Includ	ling Author, Title, Date, l	Pertinent Pa	iges, Etc.)		
	4_		<u> </u>												
	╂		-												
	+		-				_								
	1		\vdash			<u> </u>									
XAMI	NER	Λ	. [1	1	1.				DATE CONS	IDERED 7/2	1			
			Ц	<u>M</u>	<u> </u>	A.	7.	_			<u> </u>	0)			
EXAM	INE	R: Init	ial i	f cita	tion .	cons	idere	d, w	hethe	r or not citation	n is in conformance with MPEP	609: Draw lin	e through citation i	f not in	

Form PTO-1449 U.S. Departmen Patent and Tro							and	mer Tr	nt of Commo ademark Of	erce Nice		Atty. Docket No. Serial No. 60390-IA/JPW/GJG/JBC Not Yet Kr		
		-	ie^	D 2 -		10-	ı n.	· ·	Octobr o	ITATION	Applic	ants	: Arlindo Caste	lhano et al.
		TL.	ir U						LOSURE C is if necessa		Filing D Herew			Group
									U.S. PA	TENT DOCUMENT	S			
Examiner		Do	cume	nt N	umb	er			Date	Class		Subclass	Filing Date if Appropriate	
Initial	┿┈	╁╌		1	\mathbf{T}	Υ-	TT				_			
	+	╄	╀	┼	╀	╀	╀-	↓_	 				<u> </u>	
	ــــــــــــــــــــــــــــــــــــــ	Т.	1	Ц.,	1			<u>i</u>	1	1	1		l	L
<u> </u>	1	1-	1.	Τ.	-	T-	Τ.	12		PATENT DOCUME	NTS		V	
₩.	wo		. 4	1	9	<u>B</u>	4	9	9/1/94	PCT:			ļ	<u> </u>
-	wo		4	2	4	1	3	6	10/27/94	PCT;				
	wo		5	#	1	6	8	1	5/4/95	PCT;	-+			
-+	wo		5	1	8	6	벁	7	7/13/95	PCT;	+		 	
	wo		5	 !-	9	7	7	4	7/27/95	PCT;	\rightarrow		 	
$-\!$	wo		5	1	9	9	7	0	7/27/95	PCT;			 /	
	wo wo		6	2	9	5	7	7 8	8/3/95	PCT;		₩	 	
	wo		7	0	2	4 2	6	6	6/27/96	PCT:		+	 	
-+	wo		+	6	5	╬	3	8	2/13/97	PCT;		+		
$-\!$	wo		 /7	3	3	8	7	9	9/18/97	PCT;		+	 	
+	wo		8	0	7	6	2	6	2/26/98	PCT;		+	l- /	
	wo		8	6	8	3	8	2	3/5/98	PCT;		<u> </u>	 	
	wo		8	2	2	4	6	5	5/28/98	PCT:		_	\ 	
	wo	_	8	2	9	5	9	 	7/9/98	PCT:			₩	
	wo	•	8	5	7	6	5	ť	12/23/98	PCT;			χ	
	wo		9	6	6	ō	5	3	2/11/99	PCT:			/\	
\neg	wo		9	3	3	8	ſ	5	7/8/99	PCT:			/ \ 	
	wo		9	4	2	0	9	3	8/26/99	PCT;		_		
	wo		9	6	2	5	Ĺ	8	12/9/99	PCT;		\dashv	1	
	wo		ī	3	9	7	7	7	6/7/01	PCT (Exhibit 1);		+	- \ -	
	wo	02	0	5	7	2	6	7	7/25/02	PCT;		/	1	
_	wo		0	4	8	1	2	0	6/12/03	PCT (Exhibit 2);		_	· · · /	
	EP	0	3	2	2	2	4	2	6/28/89	EPO:	- /			
	EP	0	5	1	4	5	4	0	11/25/92	EPO;	1/		\ <u></u>	
	EP	0	6	8	2	0	2	7	11/15/95	EPO;	$\Box I$			
	EP	0	7	2	9	7_	5	8	9/4/96	EPO;	/			
M	EP	0	7_	7	3	0	2	3	5/14/97	EPO;	l		· ·	
				Ĺ	L		L							
			0	TH	ER	DO.	CUI	ME	NTS (Includ	ling Author, Title, Da	te, Pertinen	ıt Pa	ages, Etc.)	
		匚												
\longrightarrow		<u> </u>												
		₩.												
		Ļ		Λ										
EXAMINE	R D	1		11.	,				DATE CONS	IDERED ス/コ/	1/15			
	44	717	<u>~</u>	11	4	1			l	<u> </u>	0.2			
EXAMIN	ER: in	tial i	f cita	tion	coya	idere	d, w	heth	er or not citatio	n is in conformance with M	IPEP 609: Dra	w lic	ne through citation it	not in
nformanc	e and n	ot co	nside	ered.	Inch	ude c	ору	of th	is form with no	xt communication to applic	ant.		-	

										•			Paj	ge 3 of 6
orm P	rO-144	9							nt of Comme		Atty. Doc 60390-1A/	ket No. JPW/GJG/JBC	Serial	
INFORMATION DISCUASING OUTLANDS												s: Arlindo Cast	elhano e	et al.
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Filing Date Herewith		Group		
U.S. PATENT DOCUMENTS														
xaminer iltial	\perp	D∞	umei	nt Nu	ımbe	er T		_	Date	Name	Class	Subclass	Filing D	
		┡	<u> </u>	L	-	╀	+-	┞				_	<u> </u>	
		Ͱ	_	\vdash	<u> </u>	╀	+	 	ļ			 	 	
		<u> </u>	<u> </u>	<u> </u>	<u></u>	_		l			<u> </u>	<u> </u>	<u> </u>	
		L .	cum		N				-,	PATENT DOCUMEN		T	L	
		۳۵۰	cum	ent	NU	mo	er		Date	Country	Class	Subclass	Trans	1
m	GB	0	9	ı	5	3	Ю	3	1/9/63	Great Britain;		 	Yes	No
// V.	DE	3	1	4	5	2	8	7	5/19/93	Germany;	+		 	_
A	IN	0	1	_	7	2	8		2/22/86	India;				
<i>10</i> , Y. (/	JP	09		9]] []]	<u> </u>	8	•	5/11/999	Uapan:			1	
Δ.//		Аb	brac	chi	o M	1	et al.	<u>aler</u> . (1	999) "Brain	ng Author, Title, Dat Adenosine Receptor	s as Tare		itic Inte	rvention
DA		Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention Neurodegenerative Diseases", Ann. NY, Acad. Sci., 890: 79-92; Banker, G.S. et al., Modern Pharmaceutics, 3 rd ed., Marcel Dekker, New York, 1996, page 596;												
		Ba	nker	<u>, G</u>	.S.	et a	al., <u>N</u>	(ode	em Pharmac	eutics, 3rd ed., Marc	el Dekker, Ne	w York, 1996,	page 59	96;
11		Bai Pha	reii im:	, K. Icol	J. (. I. Sc	195 3C.	39: (кеа 51-6	lizing the Po i6:	otential of Adenosine	-Receptor-Ba	ased Therapeuti	cs" <u>Pro</u>	c. West
	·	Bai	rett	, R.	J. 6	et a	al., "	N-0	861 selectiv	ely antagonizes ade	nosine Al re	eceptors in viv	o" Euro	pean J
+									6: 9-16; Adenosine A	1 and A3 receptors r	nediate inhih	ition of supportion	tronomi	innian ir
_1_1		rat	cort	ical	ne	uro	ns",	Ne	uropharmace	ology, 40: 85-95;		- •	•	
Π		Bu	ndy,	. G.I	L. e	t al	. (19	95)	"Synthesis o	f Novel 2,4-Diamino	рупою-[2,3-с]pyrimidines w	ith Anti	oxidant
-	•	Car	nnh	ell.	ecti R	<u>ve,</u> M	and	An al	"Selective	tivity" <u>J. Med. Chem</u> A ₁ -Adenosine Rec	1, 38: 4161-4	163;	1 Hoine	Vana
\perp		Sac	cha	ron	1900	<u>es (</u>	Cere	visio	e Functiona	l Assays" Bigorg. &	Med. Chem.	Lett. (1999) 9(1	6): 241	3-2418
		Ch	en, Y	Y. L	, e	t al	., "S	yntl	nesis and Or	al Efficacy of a 4-(B	utylethylamin	ю)рупою[2,3-а]pyrimi	dine: A
11			10 a i			ive	Con	uco	порт-кете	sing Factor, Recept	or Antagonisi	r, (1997) <u>J. M</u>	ed. Che	<u>:m.</u> , 40:
		Cui	mmi	ngs	, J.	et a	al., "	Ant M	agonism of t	he Cardiodepressant 00), 7(8): 618-624;	Effects of Ad	enosine during	Acute H	ypoxia'
\sqcap		Del	Nini	10,	M.I	P. i	n A	ากน	al Reports i	n Medicinal Chemis	try, Vol. 33,	(Academic Pre	ss: San	Diego
\dashv)8), aina					lew	Purines and	Purine Analogs as M	fodulators of	Multidaya Dasi	otanaa''	I Mad
		Che	m.	(19	96)	39	: 40 <u>9</u>	99-4	108;			_	•	
$\perp \! \! \perp$		Rec	ept	or A	\ffi	nity	<u>y'' Bi</u>	oor	g. Med. Che	eture-Activity Studies vm. (1996), 4(6): 923	-934;	_	_	
		Fec 148	ktis -15	tovo 3;	e, I.	el	al., (199	8) "Adenosi	ne A ₂₈ receptors: a n	ovel therapeu	tic target in asth	ma?", <u>]</u>	<u>iPS</u> 19:
ml		Gad), E	. e	tal	••	'Ade	nos	ine Al Re	ceptor Antagonist P	rolongs Surv	vival in the Hy	poxic	Rat" J.
1.71		<u>car</u>	alo	vas	cuic	r I	nar	m. (<u> 2001) 38: 3</u>					
CAMINE	D /1	1 '				u i				DATE CONSIDER	- 1 m			

Form PTO-	1449			•		ent of Comme ademark Off			Atty. Docket No. 60390-IA/JPW/GJG/JBC					
	DATE	ODA	ATT	ON T	1100	LOSURE CIT	ra tion	Applicants: Arlindo Castelhano et al.						
	IM					ts if necessar;		Filing Date Herewith	Group					
						U.S. PAT	TENT DOCUMENTS							
Examiner Initial	Docu	ment N	umbe	r		Date	Name	Class	Subclass		Filing Date if Appropriate			
									•					
·						FOREIGN I	PATENT DOCUMEN	TS	_					
	Doc	ument	Nu	mber		Date	Country	Class	Subclass	Transl	ation			
	- i						1			Yes	No			
			T		T	1				1	1			
	- -	+-	十	\vdash	+				 	1 -				
		ОТН	FR I	חחרו	IME	NTS (Includi	ng Author, Title, Date	Partinent P	egge Ftg)		•			
	Han									•				
\./I		Hart, H. et al., Organic Chemistry, A Short Course, (Houghton Mifflin: 1995), p. 121; Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists a												
JYI	Antagonists" J. Med. Chem., 26: 838-844; Jacobson K.A., et al., (1998) "Adenosine A3 receptors: novel ligands and paradoxical effects",]													
1														
Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A3 Adenosine														
										osine Re	sine Receptor-			
		selective Antagonists", <u>Neuropharmacology</u> , 36 (9): 1157-1165; Jorgensen, A. et al. (1985) "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines" <u>Liebigs, Ann. Chem.</u>												
	Page	s 142	2-148	8;										
	Disc	overy	Too	day 4	(12):	542-551;) "Adenosine recepto	.		•				
1							of pyrazinecarboxyl			derivs.	of 3			
							I) Yakugaku Zasshi 8							
1. 1	role	T., et	al., (and	1999 A3 r) "Pr ecent	otective effectors". 72 nd Sc	ets of renal ischemic principles of the	reconditionii e American F	ng and adenosi: Jeart Association	ne pretre on. Atlar	atment			
1 1		role of A1 and A3 receptors", 72 nd Scientific Sessions of the American Heart Association, Atlanta, GA p.197;												
	Lee	T., et	al., (2000) "Pr	otective effec	ts of renal ischemic p	reconditionii	ng and adenosis	ne pretre	atment			
	role	of Al	and	1 A3	recep	tors", <u>Am. J.</u>	Physiol. Renal Physi	<u>ol., 278: F38</u>	30-F387;					
1							of Bronchial Asthm	a with Ade	nosine Recept	or Ago	nists o			
							4(2): 89-100;		20171					
1		itner, I <u>m.</u> 26					xyribonucleic Acid Cr	oss-linking A	rgents. 8,8'-Bis	purines''	, <u>J. Org</u>			
<u>//</u>							2-phenyladenines: Str	ucture-Activ	ity Relationshi	ns of Po	tent A			
BM11							onists" <u>J. Med. Chem</u>			ps 01 1 0				
<u> </u>														
EXAMINER 7	4 Ha	N	 ان <i>ا</i>	0-		DATE CONSI	DERED 3/3/09	<u> </u>	· · ·					
EXAMINER	: Initial if	citation			wheth	er or not citation	is in conformance with MP	EP 609: Draw li	ne through citation	if not in				

Form I	 PTO	-1449)		U.S. I	Depart	me	nt of Comme	Atty. Doc	ket No.	Serial No.				
	=					-		ademark Off			JPW/GJG/JBC		t Known		
			INFO	RM	ATI(ON DE	SCI	LOSURE CIT	TATION	Applicant	ts: Arlindo Cast	<u>elhano e</u>	t al.		
<u> </u>								ts if necessar		Filing Date Herewith		Group			
<u> </u>						<u> </u>		U.S. PAT	TENT DOCUMENTS	<u> </u>					
Examine Initial	er		Docume	nt Nu	umber		_	Date	Name	Class	Subclass	Filing Da			
	_			辶	\sqcup		$oldsymbol{ol}}}}}}}}}}}}}}}}}}$	<u> </u>	<u> </u>		<u> </u>				
<u> </u>					ш		丄				<u></u>				
	_	T						FOREIGN I	PATENT DOCUMEN	ITS		-,			
	I	þ	Document Number					Date	Country	Class	Subclass	Transl	ation		
		_						<u> </u>	<u> </u>	<u> </u>		Yes	No		
]			L	Ш	\bot									
	1		\Box		\square		匚		ing Author, Title, Date						
py			Muller, C.E. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A ₁ -Adenosine Receptor Antagonists" J. Med. Chem., 39: 2482-2491; Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonists: Structures and Potential												
			Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonists: Structures and Potentia Therapeutic Applications", Current Pharmaceutical Design, 2: 501-530;												
 	+											7(5): 41	9-440:		
	1	<u> </u>	Muller, C. E. (1997) "A ₁ -Adenosine Receptor Antagonists", Exp. Opin. Ther. Patents 7(5): 419-4 Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethy												
			propar _i 4396-4	gylx 1405	kanth 5;	ine De	eriv	atives, A _{2A} -S	Selective Adenosine l	Receptor An	tagonists", <u>J. M</u>	1ed. Che	<u>:m.</u> , 40:		
			Vasoco	onst	rictio	on'' <i>J</i> . <i>I</i>	Pha	arm. Exp. Th	Receptor Antagonist liner. (1999), 291: 988-	-993;					
		p	Nyce, J 385: 72	J. W	. and	Metz	ger	, J.W., (1997	7) "DNA antisense the	rapy for asthr	ma in an animal	model",	Nature.		
	\top	I	Pichler	r, H.	. et al	. "Syn	the	se von 7-uns	substituierten 7H-Pyrro	olo[2,3-d] pyr	imidinen", (198	36) Liebi	gs Ann.		
	↓_		Chemic	<u>e., 9</u>	9: 148	85-15C	05;		·						
									Reaktion am 2-Amino-			pyrimidi	n-4-on,		
-	\vdash								ls "Q" (1977) <u>Chem. I</u> al Sci., (1997) 86:765		52-1469;				
	+-								K* current in human		helial cells by	exogen	ous and		
		a	utocri	ne a	adenc	osine''	Am	L. J. Physiol.	. Cell Physiol. (2001),	, 281: C1991	I-C2002;				
		7	Venuge	opal	lan,	B. et	al.	(1998) "Sy	ynthesis of 6,7-Dime	thoxypyrimi		es as P	otential		
1	T		Welch,	, W.	.J. "A	denos	ine		otor antagonists in flui		isorders" Exper	t Opin, I	nvestig.		
AWI		<u> </u>	West,	R.	A.	et al	l. ((1961) "2-A	Alkyl(aryl)-and 2,7-D	Dimethyl-4-s	ubstituted Am	inopyrro	olo[2,3-		
77.01	╁─	\dashv	Іругіі	niux	nes	<u> 1. U.y</u>	<u>با .</u>	<u>hem., 26: 38</u>	309-3812;						
EXAMIN	VER	A	(fo)	_	V	70	_	DATE CONSI	DERED 3/3	705					
*EXAMI	INEF	R: Initia	if ciui conside	tion (consid Includ	ered, while copy o	iethe of thi	or not citation is form with nex	is in conformance with MP	EP 609: Draw Ii	ine through citation	if not in			

Form PTO-	1449					erce Tice	Atty. Dock 60390-IA/J	Serial Not Yet						
										Applicants	: Arlindo Caste	lhano e	t al.	
	IN	FO:			-			SURE C		Filing Date Herewith		Group		
								U.S. PA	TENT DOCUMENTS					
Examiner Initial	Doc	ume	nt Nu	ımbı	:r			Date	Name	Class	Subclass	Filing Date if Appropriate		
ANI	20	20 02 0			7	8	2	3/7/02	Castelhano et al. (Exhibit 3, claims only);	-7	1			
	20	02	00	58	6	6	7	5/16/02	Castelhano et al. (Exhibit 4, claims only);					
	20	03	00	36	5	4	5	2/20/03	Castelhano et al. (Exhibit 5, claims only);	1	. /			
	20	02	00	94	9	7	4	4/17/03	Castelhano et al. (Exhibit 6, claims only);		/			
\top	20	03	00	73	7	0	8	4/17/03	Castelhano et al. (Exhibit 7, claims only);	1	/		-	
	09	4	5	4	0	7	4	12/2/99	Castelhano et al. (Exhibit 8, claims only);				,	
	09	4	5	4	0	7	5	12/2/99	Castelhano et al. (Exhibit 9, claims only);					
	10			0	0	9	2	11/30/01	Castelhano et al.;	7				
pup	20	03	00	45	5	3	6	3/6/03	Castelhano et al. (Exhibit 10, claims only);	1.				
			<u> </u>					FOREIGN	PATENT DOCUMENTS		<u> </u>	 	-	
	Dο	cun	ænt	Nu	mbe	r		Date	Country	Class	Subclass	Transl		
												Yes	No	
		_	lacksquare	_	L									
-	_	┢	╂─	├	├	-	╂─	ļ <u>.</u>	-			-		
		<u> </u>	TH	ER	DΩ	CLE	ME	NTS (Includ	ling Author, Title, Date, I	ertinent P	ages, Etc.)			
ANP	Wi	llia	ms,	E. I	₹. et	al.,	"N	ucleoside tr	ransport sites in a cultured Eye Research, 13: 109-1	human ret	inal cell line est	ablished	by SV-	
1	Wo	olff,	Ma	nfn	ed l	Ξ., <u>Į</u>	3ur	ger's Medic	inal Chemistry and Drug	Discover	y. 5 th ed., Volui	ne I: Pr	inciples	
	and	1 Pr	acti	ce,	Joh	n W	ile	y & Sons, I	995, pages 975-977; 991) "Characterization of	Adenosia	e A recentor F	Rinding	Sites in	
	Во	vin	e Re	tin	al M	<u>lem</u>	bra	nes", Expe	rimental Eye Research, 5	<u>3: 325-331</u>	; and			
ano	Zh	ao,	Z. e	t al.	, "E	ioa	ctiv	ation of 6,7	'-Dimethyl-2,4-di-1-pyrro at Bind Covalently to Ma	lidinyl-7H	I-pyrrolo[2,3-d]	pyrimic	line (U	
0.1								996) 9: 123		Cionioiccu	ics and I roduct	Conod		
														
EXAMINER\	11	1					-	DATE CONS	SIDERED 7/3/x0	<u> </u>	,			
H	111-	<u>. V</u>	4	<u>۸:</u>	-				3/09					
									on is in conformance with MPEP ext communication to applicant.	609: Draw ti	ne through citation	if not in		